Fundraising FoxUnveil Pharma
Venture capitalBoston · Pre-Seed–Series A · 1 people tracked
Find your way into Unveil Pharma
Sign up to see every warm intro you have to Unveil Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Unveil Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
UNVEILpharma invests in early-stage biotech companies with curated technologies that have a clear path to exit within five years. The firm leverages world-class deal flow from academic institutions like Harvard and MIT, and provides operational value through deep expertise in drug development and commercialization.
Source: firm website, verified Aug 6, 2026.
Team · 1 people
from public directories
Jorge Cortell is Executive Director of TECH Tokyo, a public benefit corporation, and Visiting Professor at Institute of Science Tokyo. He has founded seven bootstrapped startups across four countries and five industries, with five exits and one unicorn valuation, and serves on advisory boards for companies in healthcare, AI, and crisis management. His healthcare technology innovations have been deployed to diagnose and treat 80 million patients across 15 countries, including pioneering work in open-source AI platforms for healthcare, digital pathology, precision medicine software, and augmented reality surgery systems.
Frequently asked questions
- What stage does Unveil Pharma invest at?
- Unveil Pharma invests at the Pre-Seed, Seed, Series A stages.
- What sectors does Unveil Pharma focus on?
- Unveil Pharma focuses on Biotech.
- Where is Unveil Pharma located?
- Unveil Pharma is headquartered in Boston, US.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Blackbird is a venture capital firm that backs founders from the earliest stages, with a focus on ambitious technology startups across Australia and New Zealand.
Blueyard is a small equal partnership with offices in the US and Europe, investing in early-stage companies.